Capvizr
News · All summaries
Healthcare & Life Sciences
Realmind Biotech
Series C$7.4 million
RoundSeries C
Amount$7.4 million
HQNanjing, China
DateSeptember 28, 2026
THE DEAL, AT A GLANCE

Realmind Biotech

From the announcement
What it doesRealmind Biotech develops Vitro diagnostic devices intended for medical assessments.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Who is involvedBacked by our team of analystsFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
What happenedRealmind Biotech raised $7.4M Series C, announced 2026-09-28From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Why it mattersRealmind Biotech's $7.4M Series C supports a diagnostics company moving production to Huangshan while developing in vitro diagnostic devices for medical assessments.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Realmind Biotech · Financing Record

Explore source-linked visual explanations for Realmind Biotech. Unsupported claims are withheld while source review continues.

Record 12943 · Recorded date: 2026-09-28

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime